Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT); Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 23
States / cities: Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Torrance, California + 15 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis, Quality of Life
Interventions: Massage Therapy; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Epilepsy
Interventions: levetiracetam, Lamotrigine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Narcotic Addiction
Interventions: NADA Protocol, Medication management; Procedure · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cisplatin Induced Hearing Loss
Interventions: OTO-104; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV
Interventions: PRO 140, Placebo; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obsessive Compulsive Disorder
Interventions: CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 5 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 60
States / cities: Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more

Conditions: Autism Spectrum Disorders, Normal Hearing, Normal Intelligence, Exhibit Self- Stimulating or Ritualistic Behaviors
Interventions: ProFoveate; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Obesity
Interventions: Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON); Dietary Supplement · Behavioral
Lead sponsor: Kyle Flack; Other
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 3,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more

Conditions: Non-segmental Vitiligo
Interventions: AS012, Placebo; Drug
Lead sponsor: Ache Laboratorios Farmaceuticos S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more

Conditions: Mucositis, Pain, Leukemia
Interventions: Real Acupuncture, Sham Acupuncture; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease, Kidney Disease, Kidney Disease, Chronic, Chronic Kidney Disease (CKD), CKD
Interventions: Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray, Placebo IV, Placebo Glutathione IV, Placebo Spray; Biological · Drug · Other
Lead sponsor: Adia Med of Winter Park LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Winter Park, Florida

Conditions: Asthma
Interventions: beclomethasone, fluticasone; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions: Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 20
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Dietary regimen; Drug · Dietary Supplement
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 76
States / cities: Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more

Conditions: HIV-1-infection, Elevated Cardiovascular Risk
Interventions: CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 45 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: Osteoarthritis, Knee
Interventions: Lumiracoxib; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,464 participants
Timeline: Started 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Participants
Interventions: Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo; Biological · Drug
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Inflammatory Bowel Diseases, Psychological
Interventions: Biofeedback Enhanced Treatment; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Iron Deficiency, Iron Deficiency Anemia
Interventions: Vitamin E, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Months to 2 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis

Cognitive Effects of Treatment of Interictal Discharges

Auricular Acupuncture to Facilitate Outpatient Opioid Weaning

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

Overlapping Neural Circuits in Pediatric OCD

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Acupuncture for Mucositis Pain in Cancer Care

Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Stress in Inflammatory Bowel Disease

Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E